. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Cancer Discov. 2011 Sep 9;1(5):408–419. doi: 10.1158/2159-8290.CD-11-0131

Table 2.

VE (ATP) against 1-year persistence with HPV16 stratified by HPV16 and HPV18 serology at enrollment

HPV serology^a,^b	Arm	Women, N	Women with events, n	Rate per 100 women	95% CI	Rate reduction per 100 women	95% CI	VE, %	95% CI
HPV16 serology negative	Vaccine	1,875	4	0.2	0.1–0.5	2.5	2.0–2.8	92.2	80.3–97.6
HPV16 serology negative	Control	1,856	51	2.7	2.1–3.6	2.5	2.0–2.8	92.2	80.3–97.6

HPV16 serology positive	Vaccine	558	4	0.7	0.2–1.7	0.7	−0.5 to 1.7	50.6	−63.3 to 87.0
HPV16 serology positive	Control	551	8	1.5	0.7–2.7	0.7	−0.5 to 1.7	50.6	−63.3 to 87.0

HPV18 serology negative	Vaccine	1,853	4	0.2	0.1–0.5	2.2	1.6–2.4	90.9	76.7–97.2
HPV18 serology negative	Control	1,854	44	2.4	1.8–3.1	2.2	1.6–2.4	90.9	76.7–97.2

HPV18 serology positive	Vaccine	563	3	0.5	0.1–1.4	2.1	0.6–2.9	79.4	33.5–95.3
HPV18 serology positive	Control	541	14	2.6	1.5–4.2	2.1	0.6–2.9	79.4	33.5–95.3

The stratification by HPV16 serology excludes 31 and 45 subjects without HPV16 serology results from the vaccine and control arm, respectively.

The stratification by HPV18 serology excludes 48 and 57 subjects without HPV18 serology from the vaccine and control arm, respectively.